Rigel to start own for PhII on asthma syk compound from Pfizer fallout
This article was originally published in Scrip
Executive Summary
Pfizer's decision to halt its allergy and respiratory R&D programmes has resulted in the company returning rights for an early-stage asthma candidate, R343, to Rigel Pharmaceuticals. The candidate – a syk inhibitor for allergic asthma – has shown promise in Phase I trials and Rigel plans to begin designing a Phase II programme later this year. Rigel chairman and CEO, James Gower, said R343 will now become Rigel's most advanced in-house project.